Y
Youheng Shu
Researcher at Merck & Co.
Publications - 13
Citations - 384
Youheng Shu is an academic researcher from Merck & Co.. The author has contributed to research in topics: T-type calcium channel & Calcium channel. The author has an hindex of 8, co-authored 12 publications receiving 368 citations. Previous affiliations of Youheng Shu include Schering-Plough.
Papers
More filters
Journal ArticleDOI
Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist.
William D. Shipe,James C. Barrow,Zhi Qiang Yang,Craig W. Lindsley,Craig W. Lindsley,F. Vivien Yang,Schlegel Kelly-Ann,Youheng Shu,Kenneth E. Rittle,Mark G. Bock,Mark G. Bock,George D. Hartman,Cuyue Tang,Jeanine E. Ballard,Yuhsin Kuo,Emily D. Adarayan,Thomayant Prueksaritanont,Matthew M. Zrada,Victor N. Uebele,Cindy E. Nuss,Thomas M. Connolly,Scott M. Doran,Steven V. Fox,Richard L. Kraus,Michael J. Marino,Michael J. Marino,Valerie Kuzmick Graufelds,Hugo M. Vargas,Hugo M. Vargas,Patricia B. Bunting,Martha Hasbun-Manning,Rose M. Evans,Kenneth S. Koblan,John J. Renger +33 more
TL;DR: Structural modification of the p Piperidine leads 1 and 2 afforded the fluorinated piperidine ( S)- 5, a potent and selective antagonist that displayed in vivo CNS efficacy without adverse cardiovascular effects.
Journal ArticleDOI
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
Zhi-Qiang Yang,James C. Barrow,William D. Shipe,Kelly-Ann S. Schlegel,Youheng Shu,F. Vivien Yang,Craig W. Lindsley,Craig W. Lindsley,Kenneth E. Rittle,Mark G. Bock,Mark G. Bock,George D. Hartman,Victor N. Uebele,Cindy E. Nuss,Steven V. Fox,Richard L. Kraus,Scott M. Doran,Thomas M. Connolly,Cuyue Tang,Jeanine E. Ballard,Yuhsin Kuo,Emily D. Adarayan,Thomayant Prueksaritanont,Matthew M. Zrada,Michael J. Marino,Michael J. Marino,Valerie Kuzmick Graufelds,Anthony G. DiLella,Ian J. Reynolds,Hugo M. Vargas,Hugo M. Vargas,Patricia B. Bunting,Richard Woltmann,Michael M. Magee,Kenneth S. Koblan,John J. Renger +35 more
TL;DR: Compound 30 demonstrated a robust reduction in the number and duration of seizures at 33 nM plasma concentration, with no cardiovascular effects at up to 5.6 microM, and is a useful tool for probing the effects of T-type calcium channel inhibition.
Patent
Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
Wong Michael K C,Youheng Shu,Wensheng Yu,Stuart B. Rosenblum,Joseph A. Kozlowski,Brian F. Mcguinness,Yuefei Shao,Douglas W. Hobbs +7 more
TL;DR: In this paper, a new piperazine-piperidine substituted with pyridyl and phenyl groups, having CXCR3 antagonist activity; a pharmaceutical composition containing one or more such antagonists, each combined with another(other) compound(s) having chemokine activity.
Patent
Pyridyl amide t-type calcium channel antagonists
James C. Barrow,Kelly-Ann S. Bieber,Rowena V. Cube,Mamio Christa Mattern,Thomas S. Reger,Youheng Shu,Zhi-Qiang Yang +6 more
TL;DR: In this article, the pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-Type calcium channels are involved are presented.
Journal ArticleDOI
Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists.
Schlegel Kelly-Ann,Zhi Qiang Yang,Thomas S. Reger,Youheng Shu,Rowena V. Cube,Kenneth E. Rittle,Phung Bondiskey,Mark G. Bock,George D. Hartman,Cuyue Tang,Jeanine E. Ballard,Yuhsin Kuo,Thomayant Prueksaritanont,Cindy E. Nuss,Scott M. Doran,Steven V. Fox,Susan L. Garson,Richard L. Kraus,Yuxing Li,Victor N. Uebele,John J. Renger,James C. Barrow +21 more
TL;DR: 45 was identified as a potent T-type Ca(2+) channel antagonist with minimized PXR activation in a rat model of absence epilepsy and showed significant alterations of sleep architecture after oral dosing to rats as measured by EEG.